Insider · CIK 0001168581
Goldman Myla Lai
Files at WST (WEST PHARMACEUTICAL SERVICES INC), QTRX (Quanterix Corp), AKYA (Akoya Biosciences, Inc.). First filing -, latest -.
Goldman Myla Lai files SEC Form 4 as director at WST (WEST PHARMACEUTICAL SERVICES INC), and also at QTRX (Quanterix Corp), AKYA (Akoya Biosciences, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Goldman Myla Lai has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 4, 2026 | WST WEST PHARMACEUTICAL SERVICES INC | AGrant or award Common Stock | +791 | $0.00 | $0 | 20,435 | May 6, 2026 |
| Jan 2, 2026 | QTRX Quanterix Corp | AGrant or award Common Stock | +23,372 | $0.00 | $0 | 52,860 | Jan 6, 2026 |
| Jan 2, 2026 | QTRX Quanterix Corp | AGrant or award Common Stock | +1,944 | $0.00 | $0 | 54,804 | Jan 6, 2026 |
| Oct 1, 2025 | QTRX Quanterix Corp | AGrant or award Common Stock | +2,084 | $5.54 | $12k | 29,488 | Oct 3, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Common Stock | -20,000 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | QTRX Quanterix Corp | AGrant or award Common Stock | +2,940 | - | - | 2,940 | Jul 10, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Stock Option (Right to Buy)derivative | -38,993 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | QTRX Quanterix Corp | AGrant or award Common Stock | +24,464 | $0.00 | $0 | 27,404 | Jul 10, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Stock Option (right to buy)derivative | -30,549 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | QTRX Quanterix Corp | AGrant or award Stock Option (right to buy)derivative | +50,758 | $0.00 | $0 | 50,758 | Jul 10, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Stock Option (right to buy)derivative | -56,322 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| May 6, 2025 | WST WEST PHARMACEUTICAL SERVICES INC | AGrant or award Common Stock | +1,071 | $0.00 | $0 | 19,424 | May 8, 2025 |
Questions about Goldman Myla Lai
Answered from the filings on this page, as of the latest one.
Is Goldman Myla Lai buying or selling?
Goldman Myla Lai has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Goldman Myla Lai's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Goldman Myla Lai has 0.
Where does Goldman Myla Lai file Form 4?
Goldman Myla Lai has filed Form 4 at WST (WEST PHARMACEUTICAL SERVICES INC); QTRX (Quanterix Corp); AKYA (Akoya Biosciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.